Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility
Open Access
Abstract
This commentary attempts to discuss the required standardization of circulating tumor DNA (ctDNA) analyses and thereby improve the clinical validity of ctDNA monitoring in the metastatic setting of solid tumors.Keywords
Funding Information
- Kræftens Bekæmpelse
This publication has 43 references indexed in Scilit:
- Content of circulating tumor DNA depends on the tumor type and the dynamics of tumor size, but is not influenced significantly by physical exercise, time of the day or recent mealCancer Genetics, 2021
- Early ctDNA response to chemotherapy. A potential surrogate marker for overall survivalEuropean Journal of Cancer, 2021
- Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatmentEuropean Journal of Cancer, 2021
- How to use liquid biopsies to treat patients with cancerESMO Open, 2021
- Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancerLung Cancer, 2019
- An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response RateJAMA Internal Medicine, 2019
- A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncologyEuropean Journal of Cancer, 2019
- Liquid Biopsies, What We Do Not Know (Yet)Cancer Cell, 2017
- Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS -mutated lung adenocarcinomaLung Cancer, 2016
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011